MA56469A - Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal - Google Patents
Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatalInfo
- Publication number
- MA56469A MA56469A MA056469A MA56469A MA56469A MA 56469 A MA56469 A MA 56469A MA 056469 A MA056469 A MA 056469A MA 56469 A MA56469 A MA 56469A MA 56469 A MA56469 A MA 56469A
- Authority
- MA
- Morocco
- Prior art keywords
- psma
- neonatal
- receptor
- binding antibodies
- reduced affinity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019902344A AU2019902344A0 (en) | 2019-07-02 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MA56469A true MA56469A (fr) | 2022-05-11 |
Family
ID=74100117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA056469A MA56469A (fr) | 2019-07-02 | 2020-07-02 | Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220323619A1 (fr) |
EP (1) | EP3994177A4 (fr) |
JP (1) | JP2022540385A (fr) |
KR (1) | KR20220057517A (fr) |
CN (1) | CN114555641A (fr) |
AU (1) | AU2020299025A1 (fr) |
BR (1) | BR112021026663A2 (fr) |
CA (1) | CA3141471A1 (fr) |
CL (1) | CL2021003563A1 (fr) |
IL (1) | IL289523A (fr) |
MA (1) | MA56469A (fr) |
MX (1) | MX2021015669A (fr) |
WO (1) | WO2021000018A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240051240A (ko) * | 2021-09-01 | 2024-04-19 | 테릭스 파마슈티컬스 (이노베이션스) 피티와이 엘티디 | 응집체 분리 방법 |
EP4279092A1 (fr) | 2022-05-17 | 2023-11-22 | Bayer AG | Complexes radiopharmaceutiques |
WO2023222557A1 (fr) | 2022-05-17 | 2023-11-23 | Bayer Aktiengesellschaft | Complexes radiopharmaceutiques ciblant l'antigène membranaire spécifique de la prostate et leurs combinaisons |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
CA2632094C (fr) * | 2005-12-02 | 2015-01-27 | Wayne A. Marasco | Anticorps contre l'anhydrase carbonique ix (g250), et procede d'utilisation correspondants |
KR20210094669A (ko) * | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
EP3327034A1 (fr) * | 2013-04-29 | 2018-05-30 | F. Hoffmann-La Roche AG | Anticorps anti-igf-1r aboli de liaison du récepteur fcrn et leur utilisation dans le traitement de maladies vasculaires de l'oeil |
JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
US11254744B2 (en) * | 2015-08-07 | 2022-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
WO2017212250A1 (fr) * | 2016-06-06 | 2017-12-14 | Polytherics Limited | Anticorps, leurs utilisations et leurs conjugués |
GB201614162D0 (en) * | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
-
2020
- 2020-07-02 JP JP2021578269A patent/JP2022540385A/ja active Pending
- 2020-07-02 WO PCT/AU2020/050690 patent/WO2021000018A1/fr active Application Filing
- 2020-07-02 MX MX2021015669A patent/MX2021015669A/es unknown
- 2020-07-02 BR BR112021026663A patent/BR112021026663A2/pt unknown
- 2020-07-02 CN CN202080054212.1A patent/CN114555641A/zh active Pending
- 2020-07-02 CA CA3141471A patent/CA3141471A1/fr active Pending
- 2020-07-02 EP EP20835081.9A patent/EP3994177A4/fr active Pending
- 2020-07-02 MA MA056469A patent/MA56469A/fr unknown
- 2020-07-02 KR KR1020227002845A patent/KR20220057517A/ko unknown
- 2020-07-02 US US17/622,333 patent/US20220323619A1/en active Pending
- 2020-07-02 AU AU2020299025A patent/AU2020299025A1/en active Pending
-
2021
- 2021-12-29 CL CL2021003563A patent/CL2021003563A1/es unknown
- 2021-12-30 IL IL289523A patent/IL289523A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220057517A (ko) | 2022-05-09 |
JP2022540385A (ja) | 2022-09-15 |
WO2021000018A1 (fr) | 2021-01-07 |
EP3994177A4 (fr) | 2023-09-20 |
CL2021003563A1 (es) | 2022-11-18 |
US20220323619A1 (en) | 2022-10-13 |
MX2021015669A (es) | 2022-04-18 |
CA3141471A1 (fr) | 2021-01-07 |
CN114555641A (zh) | 2022-05-27 |
IL289523A (en) | 2022-03-01 |
BR112021026663A2 (pt) | 2022-04-12 |
EP3994177A1 (fr) | 2022-05-11 |
AU2020299025A1 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA56469A (fr) | Anticorps de liaison à psma avec une affinité réduite pour le récepteur fc néonatal | |
WO2017123650A3 (fr) | Protéines de fusion se liant à gitr multivalentes et multispécifiques | |
MA54513A (fr) | Molécules de liaison à l'antigène cd28 agonistes de ciblage de tumeurs | |
MA55688A (fr) | Réglage de la temporisation de harq pour pdsch avec indicateur de temporisation pdsch à harq en attente | |
IL276459A (en) | Variable regions of an antibody that targets the NKG2D receptor | |
WO2017123673A3 (fr) | Protéines de fusion multivalentes et multispécifiques fixant ox40 | |
SI3313879T1 (sl) | Protitelesa z antitransferinskim receptorjem s prilagojeno afiniteto | |
MA47200A (fr) | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb | |
MA52182A (fr) | Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl | |
MA38797A1 (fr) | Protéine de fusion thérapeutique | |
FR3036774B1 (fr) | Dispositif lumineux, notamment pour vehicule automobile, et boitier d'eclairage comprenant un tel dispositif | |
IL284091A (en) | Antibodies neutralize the type 2 immunoglobulin-like leukocyte receptor | |
IL289524A (en) | Antibodies to carbonic anhydrase ix with reduced affinity for the neonatal fc receptor | |
HK1244016A1 (zh) | FC融合高親和力IGE受體α鏈 | |
MA51213A (fr) | Vitrage de véhicule comprenant une platine à ergots pour la fixation d'un accessoire, et platine | |
FR3021373B1 (fr) | Dispositif d'articulation a rotule pour une turbomachine. | |
MA53094A (fr) | Protéine de liaison à l'antigène anti-steap1 | |
MA52075A (fr) | Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-l1 | |
MA51750A (fr) | Appareil d'égalisation d'usure pour cyclones | |
MA50586A (fr) | Procédés d'évaluation de l'affinité de liaison d'une variante d'anticorps au récepteur fc néonatal | |
FR3024189B1 (fr) | Dispositif de fixation d'une piece sur un support avec compensation d'un ecart entre la piece et le support, element de reglage et unite de reglage d'un tel dispositif | |
FR3032658B1 (fr) | Dispositif d'articulation pour le reglage de l'inclinaison d'un dossier de siege | |
EP4073114A4 (fr) | Anticorps anti-albumine sérique | |
MA54464A (fr) | Anticorps humanisé anti-récepteur de l'igf-i | |
MA56397A (fr) | Protéines de liaison à l'il1rap |